Palatin Technologies (PTN) Set to Announce Quarterly Earnings on Wednesday

Palatin Technologies (NYSEAMERICAN:PTNGet Free Report) is scheduled to be announcing its earnings results on Wednesday, September 20th.

Palatin Technologies Price Performance

Shares of PTN stock opened at $1.86 on Tuesday. The company has a current ratio of 2.05, a quick ratio of 1.99 and a debt-to-equity ratio of 0.01. The company has a fifty day moving average of $2.48. Palatin Technologies has a one year low of $1.80 and a one year high of $8.60. The firm has a market cap of $20.74 million, a price-to-earnings ratio of -0.63 and a beta of 0.95.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on PTN shares. HC Wainwright restated a “buy” rating and issued a $70.00 target price on shares of Palatin Technologies in a research note on Monday, August 7th. cut Palatin Technologies from a “hold” rating to a “sell” rating in a report on Monday.

Read Our Latest Report on Palatin Technologies

Institutional Trading of Palatin Technologies

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. CIBC Asset Management Inc bought a new stake in Palatin Technologies during the 1st quarter worth about $41,000. Dimensional Fund Advisors LP bought a new stake in shares of Palatin Technologies in the 3rd quarter valued at about $135,000. Jane Street Group LLC bought a new stake in shares of Palatin Technologies in the 1st quarter valued at about $103,000. Millennium Management LLC bought a new stake in shares of Palatin Technologies in the 4th quarter valued at about $118,000. Finally, Vanguard Group Inc. increased its stake in shares of Palatin Technologies by 0.5% in the 1st quarter. Vanguard Group Inc. now owns 9,559,564 shares of the biopharmaceutical company’s stock valued at $4,398,000 after acquiring an additional 48,812 shares during the last quarter. 7.86% of the stock is owned by institutional investors.

About Palatin Technologies

(Get Free Report)

Palatin Technologies, Inc, a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder.

Featured Stories

Earnings History for Palatin Technologies (NYSEAMERICAN:PTN)

Receive News & Ratings for Palatin Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palatin Technologies and related companies with's FREE daily email newsletter.